This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beck, M. N. Articles by Munier, F. Search for Related Content PubMed PubMed Citation Articles by Beck, M. N. Articles by Munier, F. Social Bookmarking                            What's this?

First-Line Chemotherapy With Local Treatment Can Prevent External-Beam Irradiation and Enucleation in Low-Stage Intraocular Retinoblastoma

From the Pediatric Department, Hematology-Oncology Unit, and Department of Radiooncology, Centre Hospitalier Universitaire Vaudois, and Jules Gonin Eye Hospital, Lausanne, Switzerland.

Address reprint requests to Maja Nenadov Beck, MD, Pediatric Department, Hematology-Oncology Unit, University Hospital CHUV, 1011 Lausanne, Switzerland; email mnenadov{at}hola.hospvd.ch

PURPOSE: To evaluate the efficacy of first-line chemotherapy (CT) in preventing external-beam radiotherapy (EBR) and/or enucleation in patients with retinoblastoma (Rbl).

PATIENTS AND METHODS: Twenty-four patients with newly diagnosed unilateral or bilateral Rbl received CT associated with local treatment (LT). Two to five courses of etoposide and carboplatin were administered at 3- to 4-week intervals, depending on tumor response, and were completed each time by LT.

RESULTS: Tumor response was observed in all eyes. Twenty-one of 24 patients showed a complete response (CR) that persisted at a median follow-up (FU) of 31 months (range, 4 to 41 months). Among the three patients who relapsed, two were lost to FU and one died of progressive disease. CR was achieved by CT and LT alone in 15 (71.4%) of 21 patients with less advanced disease (groups I to III). Six other patients with advanced disease (groups IV and V) experienced treatment failure and needed salvage treatment by EBR and/or enucleation. The difference between the two patient groups with regard to disease stage was statistically significant (P < .0001). EBR could be avoided in 13 (68.4%) of 19 patients, who presented with groups I to III (15 eyes) and group V (one eye) disease, whereas enucleation could be avoided in only two (40%) of five.

CONCLUSION: CT combined with intensive LT is effective in patients with groups I to III Rbl, permitting the avoidance of EBR in the majority of these young children and, thus, reducing the risk of long-term sequelae. This is in contrast with the disappointing results for patients with groups IV and V Rbl, in whom EBR and/or enucleation was needed.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Antczak, C. Kloepping, C. Radu, T. Genski, L. Muller-Kuhrt, K. Siems, E. de Stanchina, D. H. Abramson, and H. Djaballah Revisiting Old Drugs as Novel Agents for Retinoblastoma: In Vitro and In Vivo Antitumor Activity of Cardenolides Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3065 - 3073. [Abstract] [Full Text] [PDF]

				G. L. Chantada, A. C. Fandino, A. M. Carcaboso, E. Lagomarsino, M. T. G. de Davila, M. R. Guitter, A. B. Rose, J. Manzitti, G. F. Bramuglia, and D. H. Abramson A Phase I Study of Periocular Topotecan in Children with Intraocular Retinoblastoma Invest. Ophthalmol. Vis. Sci., April 1, 2009; 50(4): 1492 - 1496. [Abstract] [Full Text] [PDF]

				J. H. Kim, J. H. Kim, Y. S. Yu, D. H. Kim, C. J. Kim, and K.-W. Kim Antitumor Activity of Arsenic Trioxide on Retinoblastoma: Cell Differentiation and Apoptosis Depending on Arsenic Trioxide Concentration Invest. Ophthalmol. Vis. Sci., April 1, 2009; 50(4): 1819 - 1823. [Abstract] [Full Text] [PDF]

				S E Chung, H S Sa, H H Koo, K H Yoo, K W Sung, and D-I Ham Clinical manifestations and treatment of retinoblastoma in Korea Br. J. Ophthalmol., September 1, 2008; 92(9): 1180 - 1184. [Abstract] [Full Text] [PDF]

				A. E. Rizzuti, I. J. Dunkel, and D. H. Abramson The Adverse Events of Chemotherapy for Retinoblastoma: What Are They? Do We Know? Arch Ophthalmol, June 1, 2008; 126(6): 862 - 865. [Full Text] [PDF]

				M. Wallach, A. Balmer, F. Munier, S. Houghton, S. Pampallona, N. von der Weid, M. Beck-Popovic, and on behalf of the Swiss Pediatric Oncology Group an Shorter Time to Diagnosis and Improved Stage at Presentation in Swiss Patients With Retinoblastoma Treated From 1963 to 2004 Pediatrics, November 1, 2006; 118(5): e1493 - e1498. [Abstract] [Full Text] [PDF]

				B. Hayden, M.-E. Jockovich, T. G. Murray, M. T. Kralinger, M. Voigt, E. Hernandez, W. Feuer, and J.-M. Parel Iontophoretic delivery of Carboplatin in a murine model of retinoblastoma. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3717 - 3721. [Abstract] [Full Text] [PDF]

				D S Gombos, P A Cauchi, J L Hungerford, P Addison, P G Coen, and J E Kingston Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor? Br. J. Ophthalmol., September 1, 2006; 90(9): 1168 - 1172. [Abstract] [Full Text] [PDF]

				M. W. Wilson, B. G. Haik, and C. Rodriguez-Galindo Socioeconomic Impact of Modern Multidisciplinary Management of Retinoblastoma Pediatrics, August 1, 2006; 118(2): e331 - e336. [Abstract] [Full Text] [PDF]

				M. W. Wilson, C. H. Fraga, C. E. Fuller, C. Rodriguez-Galindo, J. Mancini, N. Hagedorn, M. L. Leggas, and C. F. Stewart Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1269 - 1273. [Abstract] [Full Text] [PDF]

				D H Abramson, S D Lawrence, K L Beaverson, T C Lee, I S Rollins, and I J Dunkel Systemic carboplatin for retinoblastoma: change in tumour size over time Br. J. Ophthalmol., December 1, 2005; 89(12): 1616 - 1619. [Abstract] [Full Text] [PDF]

				D. H. Abramson, K. L. Beaverson, S. T. Chang, I. J. Dunkel, and B. McCormick Outcome Following Initial External Beam Radiotherapy in Patients With Reese-Ellsworth Group Vb Retinoblastoma Arch Ophthalmol, September 1, 2004; 122(9): 1316 - 1323. [Abstract] [Full Text] [PDF]

				L. Sobrin, B. C. Hayden, T. G. Murray, N. Cicciarelli, I. U. Scott, E. Hernandez, X. Wu, A. M. Markoe, W. Feuer, L. Fulton, et al. External Beam Radiation "Salvage" Therapy in Transgenic Murine Retinoblastoma Arch Ophthalmol, February 1, 2004; 122(2): 251 - 257. [Abstract] [Full Text] [PDF]

				D. A. Sussman, E. Escalona-Benz, M. S. Benz, B. C. Hayden, W. Feuer, N. Cicciarelli, S. Toledano, A. Markoe, and T. G. Murray Comparison of Retinoblastoma Reduction for Chemotherapy vs External Beam Radiotherapy Arch Ophthalmol, July 1, 2003; 121(7): 979 - 984. [Abstract] [Full Text] [PDF]

				C. Rodriguez-Galindo, M. W. Wilson, B. G. Haik, T. E. Merchant, C. A. Billups, N. Shah, A. Cain, J. Langston, M. Lipson, L. E. Kun, et al. Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin J. Clin. Oncol., May 15, 2003; 21(10): 2019 - 2025. [Abstract] [Full Text] [PDF]

				E Bellaton, A I Bertozzi, C Behar, P Chastagner, H Brisse, C Sainte-Rose, F Doz, and L Desjardins Neoadjuvant chemotherapy for extensive unilateral retinoblastoma Br. J. Ophthalmol., March 1, 2003; 87(3): 327 - 329. [Abstract] [Full Text] [PDF]

				D. S Gombos, A. Kelly, P. G Coen, J. E Kingston, and J. L Hungerford Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age Br. J. Ophthalmol., January 1, 2002; 86(1): 80 - 83. [Abstract] [Full Text] [PDF]

				S.-i. Nishimura, T. Sato, H. Ueda, K. Ueda, M. N. Beck, A. Meisler, G. N. Hortobagyi, N. Ueno, M.-C. Hung, K. Mokbel, et al. Acute Myeloblastic Leukemia as a Second Malignancy in a Patient With Hereditary Retinoblastoma J. Clin. Oncol., November 1, 2001; 19(21): 4182 - 4183. [Full Text] [PDF]